FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.
Authors: Dornan David , Spleiss Olivia , Yeh Ru-Fang T , Duchateau-Nguyen Guillemette , Robak Tadeusz , Moiseev Sergey I , Dmoszynska Anna , Solal-Celigny Philippe , Warzocha Krzysztof , Loscertales Javier , Catalano John , Afanasiev Boris V , Larratt Loree , Rossiev Viktor A , Bence-Bruckler Isabelle , Geisler Christian H. , Montillo Marco , Wenger Michael K. , Weisser Martin 
Published: October 2019

Abstract 2338

Poster Board II-315

The addition of rituximab to fludarabine/cyclophosphamide chemotherapy for the treatment of both previously untreated and relapsed/refractory patients with CLL has yielded a substantial increase in PFS as demonstrated in phase III trials (Hallek et al. ASH 2008, Robak et al. ASH 2008. Polymorphisms of the FC-g-R IIIa gene (SNP 158) results in a higher (VV genotype) or lower (FV and FF genotype) affinity for IgG1 monoclonal antibodies and subsequently modulate ADCC activity. In patients with follicular NHL treated with rituximab as monotherapy it has been shown that patients displaying the higher affinity FCGR3A variant had higher response rates compared to patients displaying the lower affinity variant (Cartron et al. Blood 2002; Weng et al. JCO 2003). Furthermore, the high affinity polymorphism of the FCGR2A gene (SNP 131) (HH genotype), has also demonstrated higher response rates compared to the lower affinity variant (RH and RR genotype) in this context (Weng et al. JCO 2003). The objective of this study was to evaluate the prognostic significance of FCGR polymorphisms in patients treated with FC vs R-FC within the REACH trial. REACH was an open-label, multicenter, randomized, phase III study to evaluate the efficacy and tolerability of R-FC versus FC in relapsed or refractory patients with CD20 positive CLL (N=552). The primary endpoint of the study was progression free survival. Results from allele specific PCR for FCGR2A (SNP 131, rs1801274) and FCGR3A (SNP 158, rs396991) genes were available from n= 419 of 546 unselected patients (FC: n=209 and R-FC: n=210). In the FC arm n=29 (14%) displayed the FCGR3A VV genotype, n=96 (46%) FV genotype, and n=84 (40%) FF genotype. ). In the R-FC arm n=20 (10%) displayed the FCGR3A VV genotype, n=106 (50%) FV genotype, and n=84 (40%) FF genotype. The incidences of FCGR2A for HH, RH, RR genotypes were 27%, 49%, 24%, respectively in the FC arm and 26%, 55%, 19%, respectively in the R-FC arm. Overall, the study demonstrated prolonged PFS for R-FC vs FC treatment (HR=0.65 (0.51,0.82); p=0.00022). With respect to PFS, FCGR3A and FCGR2A polymorphisms did not demonstrate prognostic significance in the FC arm (p=0.42 and p=0.64, respectively) or R-FC arm (p=0.41 and p=0.88, respectively). Subgroup analysis revealed that those patients with lower affinity genotypes (FCGR3A: FV/FF; FCGR2A: RH/RR) benefited significantly from the addition of rituximab (HR=0.68 (0.51,0.9); p=0.0063 and HR=0.68 (0.51,0.93); p=0.014, respectively). Similar levels of benefits were suggested for those patients with higher affinity genotype (HR=0.86 (0.4,1.84); p=0.7 and HR=0.7 (0.41,1.18); p=0.18, respectively) but not statistically significant, potentially due to the lower number of patients in the high affinity groups. Multivariate analysis including FCGR genotypes, treatment arm (FC vs R-FC), Binet stage (c vs a/b), age, del(17p), IgVH mutational status revealed age (HR=1.02 (1.01,1.04); p=0.0042), binet stage HR=1.81 (1.37,2.39); p=0.000027), del(17p) (HR=2.49 (1.66,3.74); p=0.000011), treatment arm (HR=0.71 (0.54,0.92); p=0.011), IgVH (HR=2.09 (1.55-2.81); p=0.0000014), as independent prognostic factors for PFS. In summary these data demonstrate that FCGR2A and FCGR3A polymorphisms do not significantly influence the outcome of relapsed or refractory CLL patients treated with FC with or without rituximab.

Disclosures:

Dornan: Genentech, Inc.: Employment, Equity Ownership. Off Label Use: Rituximab together with FC chemotherapy in relapsed/refractory CLL. Spleiss:Roche: Employment. Yeh:Genentech, Inc.: Employment, Equity Ownership. Duchateau-Nguyen:Roche: Employment. Robak:Celgene: Consultancy; Roche: Honoraria, Research Funding; Genmab: Research Funding; Cambridge Antibody Technology: Research Funding; GlaxoSmithKline: Honoraria. Solal-Celigny:Roche: Honoraria, Research Funding. Warzocha:BMS: Consultancy, Honoraria; Celgene: Consultancy; Roche: Honoraria; Pfizer: Honoraria; Amgen: Honoraria. Loscertales:Roche: Consultancy. Catalano:Roche: Honoraria, Research Funding, Travel grants. Larratt:Roche: Honoraria; Novartis: Honoraria. Bence-Bruckler:Roche: Consultancy. Geisler:Bayer Schering: Consultancy, Research Funding, Speakers Bureau; Santaris Pharma: Consultancy; Celgene: Consultancy; Fresenius: Consultancy. Montillo:Bayer Schering: Honoraria, Research Funding, Speakers Bureau. Wenger:Roche: Employment. Weisser:Roche: Employment.